PSMA-targeting imaging agents have been investigated for potential use in RCC across several studies, however, a limitation for clinical use in nonmetastatic ccRCC is absorption of PSMA radiotracer in normal kidney parenchyma.83,84 One solution may be dynamic 68Ga-PSMA PET acquisition and analysis of radioligand kinetics, which may serve as a valuable tool in distinguishing malignant from benign renal lesions.85 Here, FOLH1 is linked to renal cell carcinoma.